Sweden · Delayed Price · Currency is SEK Isofol Medical AB Earnings Call Transcripts
Fiscal Year 2026
-
The presentation detailed a novel cancer drug's progress, highlighting strong early clinical results, a robust dose-response relationship, and a large unmet need in metastatic colorectal cancer. Expansion of clinical trials and strategic partnerships aim to accelerate development and commercialization.
Fiscal Year 2025
-
Multiple clinical and financial milestones have been achieved, including a successful rights issue, FDA and Japanese regulatory progress, and a new patent extending exclusivity to 2043. The ongoing phase 1B/2 study is advancing with higher, well-tolerated doses and an improved design, supporting strong commercial and scientific potential.
-
Exited the quarter with a strengthened financial position after an oversubscribed rights issue and continued progress in clinical trials. R&D expenses increased, resulting in a higher net loss, but positive regulatory feedback and new partnerships support future growth.